Ketorolac reduces postoperative narcotic requirements

Area of Science:

• Pediatric Surgery
• Pain Management
• Pharmacology

Background:

• Narcotic use for pediatric pain management is associated with adverse effects.
• Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is a potent analgesic but its use is limited by concerns of bleeding and nephrotoxicity.
• This study investigated ketorolac as an adjuvant analgesic in pediatric surgical patients.

Purpose of the Study:

• To evaluate the efficacy of ketorolac in reducing narcotic requirements postoperatively in pediatric surgical patients.
• To assess the safety profile of ketorolac, specifically monitoring for increased bleeding and nephrotoxicity.
• To determine if ketorolac impacts the incidence of common narcotic-related side effects.

Main Methods:

• A case-control clinical trial involving 29 pediatric surgical patients.
• Patients received either ketorolac (0.5 mg/kg IV q6h) plus morphine or morphine alone.
• Outcomes measured included narcotic requirements and incidence of respiratory depression, urinary retention, emesis, nephrotoxicity, and bleeding.

Main Results:

• Patients receiving ketorolac plus morphine required significantly less morphine in the first 48 postoperative hours compared to the control group (0.36 vs 1.08 mg/kg/d, P<.05).
• Ketorolac did not increase the incidence of adverse effects associated with morphine, such as respiratory depression, emesis, or urinary retention.
• No significant increase in bleeding or nephrotoxicity was observed in patients administered ketorolac.

Conclusions:

• Ketorolac demonstrates significant opiate-sparing effects in the immediate postoperative period for pediatric surgical patients.
• The use of ketorolac as an adjuvant analgesic in this population does not introduce additional morbidity.
• Ketorolac is a safe and effective option for multimodal pain management in pediatric surgery.